Nuclear Medicine Market Share

Regionally, the global nuclear medicine market is studied into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Amongst these markets, the market in Asia Pacific is projected to hold the largest market share by the end of 2037, owing to increasing awareness about nuclear medicine and growing investment in nuclear medicine space. For instance, in March 2022, the first full-fledged private Nuclear Medicine Center in the Northern region was officially launched by Penang Adventist Hospital, who claimed to offer its patients improved diagnostic and therapeutic options.

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of nuclear medicine is estimated at USD 15.04 billion.

The nuclear medicine market size was over USD 12.94 billion in 2024 and is set to cross USD 143.71 billion by the end of 2037, growing at more than 20.1% CAGR during the forecast period i.e., between 2025-2037. The market growth is driven by growing prevalence of cardiovascular diseases, growing geriatric population, new product launches by key players, and others.

Asia Pacific industry is poised to dominate majority revenue share by 2037, owing to increasing awareness about nuclear medicine and growing investment in nuclear medicine space in the region.

The major players in the market include GE Healthcare, Jubilant Pharmova Limited, Nordion (Canada), Inc., Bracco Imaging S.P.A, The Institute for Radioelements (IRE), NTP Radioisotopes SOC Ltd., The Australian Nuclear Science and Technology Organization (ANSTO), Mallinckrodt Pharmaceuticals, Lantheus, Eckert & Ziegler.

Nuclear Medicine Market Share